Literature DB >> 8252608

Dexamethasone target sites in the central nervous system and their potential relevance to mental illness.

M K Birmingham1, M Sar, W E Stumpf.   

Abstract

1. The topical distribution of tritiated dexamethasone (DEX), a potent synthetic glucocorticoid of widespread use in the diagnosis and assessment of mental illness, was studied in rat CNS by autoradiography to obtain information on potential target sites for feedback and other centrally mediated effects of glucocorticoids. 2. The cells of the arcuate nucleus of the hypothalamus and the lateral thalamic nuclei displayed the most concentrated nuclear accumulation of silver grains. 3. Significant accumulation, exceeding that found in the hippocampal formation, also occurred in the cells of the ventromedial, periventricular, and paraventricular nuclei of the hypothalamus, the locus ceruleus, the nucleus tractus solitarii, and the area postrema, none of which are targeted by corticosterone, the native glucocorticoid of the rat. 4. Nuclear accumulation of silver grains was prominent in neural and glial cells of the cerebral cortex, the olfactory nucleus, the dorsolateral septum, the amygdala, the subfornical organ, the lateral parabrachial, medial trapezoid, and dorsal reticular nuclei, the nucleus centralis of the raphe, the cerebellum, and vascular tissues. 5. The localization of DEX in hypothalamic and brain-stem nuclei coincided with that of the glucocorticoid receptor, possibly implicating these sites in direct or modulating effects of glucocorticoids in various forms of mental disturbance, including depression, anxiety, panic disorders, and alcohol withdrawal. 6. The extent to which various CNS regions targeted by DEX feature in negative feedback control of adrenocortical secretion remains to be defined, as does the site of impaired feedback disclosed by the dexamethasone suppression test in psychiatric patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8252608     DOI: 10.1007/bf00711578

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  43 in total

1.  The relationship between affect and the excretion of adrenaline, noradrenaline, and 17-hydroxycorticosteroids.

Authors:  G C CURTIS; R A CLEGHORN; T L SOURKES
Journal:  J Psychosom Res       Date:  1960-03       Impact factor: 3.006

2.  Immunocytochemical localization of the glucocorticoid receptor in rat brain, pituitary, liver, and thymus with two new polyclonal antipeptide antibodies.

Authors:  W C McGimsey; J A Cidlowski; W E Stumpf; M Sar
Journal:  Endocrinology       Date:  1991-12       Impact factor: 4.736

3.  Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation.

Authors:  J M Reul; E R de Kloet
Journal:  Endocrinology       Date:  1985-12       Impact factor: 4.736

4.  Distribution and coexistence of corticotropin-releasing factor-, neurotensin-, enkephalin-, cholecystokinin-, galanin- and vasoactive intestinal polypeptide/peptide histidine isoleucine-like peptides in the parvocellular part of the paraventricular nucleus.

Authors:  S Ceccatelli; M Eriksson; T Hökfelt
Journal:  Neuroendocrinology       Date:  1989-03       Impact factor: 4.914

5.  Lactate-induced anxiety.

Authors:  M R Liebowitz; E Hollander
Journal:  Biol Psychiatry       Date:  1989-03-15       Impact factor: 13.382

Review 6.  Norepinephrine in depressive reactions. A review.

Authors:  W E Bunney; J M Davis
Journal:  Arch Gen Psychiatry       Date:  1965-12

Review 7.  Pathology, phenomenology and the dopamine hypothesis of schizophrenia.

Authors:  P J McKenna
Journal:  Br J Psychiatry       Date:  1987-09       Impact factor: 9.319

8.  Hypothalamic glucocorticoid implants prevent fetal ovine adrenocorticotropin secretion in response to stress.

Authors:  T J McDonald; G E Hoffmann; D A Myers; P W Nathanielsz
Journal:  Endocrinology       Date:  1990-12       Impact factor: 4.736

9.  Mineralocorticoid response to low dose adrenocorticotropin infusion.

Authors:  M L Tuck; J R Sowers; N D Asp; S P Viosca; G Berg; D M Mayes
Journal:  J Clin Endocrinol Metab       Date:  1981-03       Impact factor: 5.958

10.  Elevated corticosteroid levels block the memory-improving effects of nootropics and cholinomimetics.

Authors:  C Mondadori; T Ducret; A Häusler
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more
  4 in total

1.  [3H]-RS-45041-190: a selective high-affinity radioligand for I2 imidazoline receptors.

Authors:  A C MacKinnon; W S Redfern; C M Brown
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

2.  Dexamethasone attenuates by colchicine induced Fos expression in the rat deep cerebellar and vestibular nuclei.

Authors:  Zdeno Pirnik; Alexander Kiss
Journal:  Cell Mol Neurobiol       Date:  2002-08       Impact factor: 5.046

3.  Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review.

Authors:  Melpomeni Peppa; Maria Krania; Sotirios A Raptis
Journal:  Integr Blood Press Control       Date:  2011-03-03

4.  Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1β and IL-6.

Authors:  Carol L Murray; Donal T Skelly; Colm Cunningham
Journal:  J Neuroinflammation       Date:  2011-05-17       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.